Status:
RECRUITING
Prophylactic Pregabalin Treatment Following Spinal Cord Injury
Lead Sponsor:
Loewenstein Hospital
Conditions:
Spinal Cord Injuries
Spinal Cord Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients arriving to rehabilitation up to 3 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.
Detailed Description
Patients arriving to rehabilitation up to 3 months following SCI will be recruited, if they have not yet developed central pain. Two thirds (the study group) will be treated with Lyrica (Pregabalin75X...
Eligibility Criteria
Inclusion
- Up to 3 months following traumatic or non-traumatic SCL
- Ability to give informed consent and cooperate
Exclusion
- Pregnancy
- Neurological or other medical conditions that may interfere with sensation
- Neuropathic-like pain before recruitment (described as painful sensation of electric current, burning, numbness, tingling, pricking, or squeezing)
- Being treated with Pregabalin
- Blood creatinine levels \>1.2 or creatinine clearance \<60
- Sensitivity to lactose
Key Trial Info
Start Date :
July 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 5 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06066918
Start Date
July 13 2021
End Date
February 5 2026
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loewenstein Rehabilitation Hospital
Raanana, Israel